Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 86, Issue 3, 2009, Pages 204-213

  Patyna, Shem ^a,c   Haznedar, J ^b   Morris, D ^c   Freshwater, K ^c   Peng, G ^a   Sukbuntherng, J ^d   Chmielewski, G ^a   Matsumoto, D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Roche   (United States)

^c PFIZER INC   (United States)

^d XenoPort Inc   (United States)

Author keywords

Antiangiogenic agent; Embryo fetal development; PDGFR inhibitor; Rabbit; Rat; Sunitinib; VEGFR inhibitor

Indexed keywords

DRUG METABOLITE; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; EMBRYO DEVELOPMENT; FEMALE; FETUS DEVELOPMENT; FETUS MALFORMATION; FOOD INTAKE; GESTATION PERIOD; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORGANOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RABBIT; RAT; SKELETON MALFORMATION; TOXICOKINETICS;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EMBRYONIC DEVELOPMENT; ENZYME INHIBITORS; FEMALE; FETAL DEVELOPMENT; FETAL VIABILITY; INDOLES; MATERNAL-FETAL EXCHANGE; MOTHERS; PREGNANCY; PYRROLES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 67649256012     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20194     Document Type: Article

References (25)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. 2003. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478.
2. Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals, Inc. 2007. NEXAVAR® (sorafenib) Prescribing Information. Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals, Inc., West Haven, CT; Emeryville, CA (available at www.nexavar.com/).
3. Blasi E, Steidl J, Patyna S, Heyen J, Hemkens M, Peng G, McHarg A. 2007. Modification of sunitinib malate (SU12488) blood pressure changes in rats. Proc Am Assoc Cancer Res 48:370-371.
4. Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, Wilkinson K, McHarg A. 2008. Evaluation of blood pressure and cardiac structure and function following treatment with sunitinib in rats. Proc Am Assoc Cancer Res 49:1133 (Abstr. 4761).
5. Demir R, Kayisli UA, Seval Y, Celik-Ozenci C, Korgun ET, Demir-Weusten AY, Huppertz B. 2004. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta 25:560-572. (Pubitemid 38701900)
6. Demir R, Seval Y, Huppertz B. 2007. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochemica 109:257-265. (Pubitemid 46962081)
7. Ferrara N. 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15-35 (discussion 35-36). (Pubitemid 32094444)
8. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442. (Pubitemid 26102720)
9. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676. (Pubitemid 36749215)
10. Genentech, Inc. Revised: November 2008. AVASTIN® (bevacizumab) Prescribing Information. Genentech, Inc., South San Francisco, CA (available at www.avastin.com/).
11. Hoch RV, Soriano P. 2003. Roles of PDGF in animal development. Development 130:4769-4784. (Pubitemid 37321862)
12. Holmes DI, Zachary I. 2005. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 6:209.
13. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M. 2006. An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076. (Pubitemid 44536887)
14. 188. Mech Dev 111:61-73.
15. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. 2003. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337.
16. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK. 2003. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766. (Pubitemid 38019277)
17. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. 2003. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605. (Pubitemid 36857948)
18. Patyna S, Arrigoni C, Terron A, Kim T-W, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W. 2008. Nonclinical safety evaluation of sunitinib: A potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 36:905-916.
19. Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J, Zimmermann RC. 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 146:1301-1311. (Pubitemid 40289317)
20. Pfizer, Inc. 2007. Data on file. New York.
21. Pfizer, Inc. 2008. SUTENT® [sunitinib malate] capsules, oral. Prescribing Information (available at www.sutent.com). New York.
22. Salewski VE. 1964. Färbemethode zum makroskopischen nachweis von implantations stellen am uterus der ratte. Colouring (staining) method for microscopic proof of uterine implantation sites in rats. Naunym-Schm Arch Exp Pathol Pharm 247:367.
23. Solomon HM, Wier PJ, Fish CJ, Hart TK, Johnson CM, Posobiec LM, Gowan CC, Maleeff BE, Kerns WD. 1997. Spontaneous and induced alterations in the cardiac membranous ventricular septum of fetal, weanling, and adult rats. Teratology 55:185-194. (Pubitemid 27283196)
24. Staples RE. 1974. Detection of visceral alteration in mammalian fetuses. Teratology 9:A-37.
25. Yamazaki Y, Morita T. 2006. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 10:515-527. (Pubitemid 44885229)